IDH wild-type GBMs with TERTp mutations exhibit particularly poor survival, reinforcing their value as prognostic biomarkers in this aggressive glioma subtype.122 These findings highlight the necessity of integrating the TERTp mutation status into glioma classification and clinical decision-making. The gene discussed is IDH2; the disease is central nervous system cancer.